BGJ398 (NVP-BGJ398): Potent FGFR1/2/3 Inhibitor for Oncology Research

Executive Summary: BGJ398 (NVP-BGJ398) is a small-molecule inhibitor with nanomolar potency against FGFR1 (IC50 0.9 nM), FGFR2 (1.4 nM), and FGFR3 (1 nM), and moderate activity for FGFR4 (IC50 60 nM) (source: product_spec). It displays over 40-fold selectivity for FGFRs versus VEGFR2 and minimal activity against other kinases (source: product_spec). In preclinical models, BGJ398 suppresses proliferation and induces apoptosis in FGFR-driven cancer cells (source: internal_article). Oral administration at 30–50 mg/kg daily delays tumor growth in FGFR2-mutant endometrial cancer models (source: product_spec). BGJ398 is supplied as a solid, is insoluble in water/ethanol, and dissolves in DMSO at ≥7 mg/mL with gentle warming (source: product_spec).

Biological Rationale

Fibroblast growth factor receptors (FGFRs) are critical for cell proliferation, differentiation, and survival. Aberrant FGFR signaling is implicated in multiple cancers, including endometrial, urothelial, and cholangiocarcinoma (source: paper). FGFR2, in particular, is a key mediator of developmental and oncogenic signaling pathways. Research using murine and guinea pig models has demonstrated that differential expression of FGFR2 and its ligands (e.g., Fgf10) governs tissue morphogenesis and cell fate decisions (source: paper). Targeting FGFRs with selective inhibitors such as BGJ398 provides a robust tool to dissect these pathways in oncology research and developmental biology (source: internal_article).

Mechanism of Action of BGJ398 (NVP-BGJ398)

BGJ398 (NVP-BGJ398) is a highly selective FGFR tyrosine kinase inhibitor. Its mechanism centers on competitive inhibition at the ATP-binding site of FGFR1, FGFR2, and FGFR3, blocking receptor autophosphorylation and downstream signaling (source: product_spec). This inhibition disrupts signal transduction cascades involving MAPK and PI3K/AKT, leading to reduced cellular proliferation and increased apoptosis in FGFR-dependent tumor cells (source: internal_article). BGJ398's >40-fold selectivity over VEGFR2 and negligible activity against kinases such as Abl, Fyn, Kit, Lck, Lyn, and Yes minimizes off-target effects (source: product_spec).

Evidence & Benchmarks

• BGJ398 exhibits IC50 values of 0.9 nM (FGFR1), 1.4 nM (FGFR2), and 1 nM (FGFR3) in biochemical kinase assays (source: product_spec).
• Shows moderate inhibition of FGFR4 (IC50 60 nM) (source: product_spec).
• Over 40-fold selectivity for FGFRs over VEGFR2, with minimal activity toward Abl, Fyn, Kit, Lck, Lyn, and Yes (source: product_spec).
• Suppresses proliferation and induces apoptosis in FGFR-dependent cancer cell lines (source: internal_article).
• Oral dosing at 30 or 50 mg/kg daily in xenograft models delays tumor growth in FGFR2-mutant endometrial cancer (source: product_spec).
• Differential FGFR2 signaling mediates tissue-specific developmental outcomes in comparative mammalian models (source: paper).

For expanded mechanistic and translational insight, see Translational Horizons in FGFR-Targeted Oncology, which surveys advanced workflow and cross-domain approaches beyond the present article.

Applications, Limits & Misconceptions

BGJ398 is widely used in oncology research for studying FGFR-driven malignancies, including cell proliferation assays, apoptosis induction studies, and xenograft tumor models (source: product_spec). It is also applied in developmental biology to interrogate the role of FGFR signaling in morphogenesis (source: paper). APExBIO supplies BGJ398 for research purposes only; it is not approved for clinical use (source: product_spec).

Common Pitfalls or Misconceptions

• BGJ398 is not soluble in water or ethanol; use DMSO (≥7 mg/mL) with warming for dissolution (source: product_spec).
• Solutions should not be stored long-term; prepare fresh before use (source: product_spec).
• Not effective in tumors lacking FGFR pathway activation; select models accordingly (source: workflow_recommendation).
• Off-target effects are minimal but not absent; confirm specificity in each system (source: product_spec).
• Only for research use; not for therapeutic or diagnostic use (source: product_spec).

See Reliable FGFR Inhibition for Oncology Research for a detailed Q&A on troubleshooting solubility and selectivity, which this piece complements by providing updated protocol parameters and comparative benchmarks.

Workflow Integration & Parameters

Protocol Parameters

• Cell viability assay | 0.1–1 μM BGJ398 | FGFR-driven cancer lines | IC50 determination, apoptosis induction | product_spec
• Xenograft study | 30–50 mg/kg/day p.o. | FGFR2-mutant models | Tumor growth delay | product_spec
• Dissolution | ≥7 mg/mL in DMSO, gentle warming | All in vitro/in vivo | Ensures full solubility | product_spec
• Storage | -20°C (solid), fresh solutions | All formats | Preserves compound integrity | product_spec
• Developmental biology assay | 0.5–2 μM | Organ culture | Modulates FGF pathway | paper
• Non-FGFR tumors | Not recommended | Off-target systems | Minimal efficacy expected | workflow_recommendation

For practical integration scenarios, refer to Next-Generation FGFR Inhibitor for Precision Research, which this article extends with new developmental biology context and updated storage guidelines.

Conclusion & Outlook

BGJ398 (NVP-BGJ398) is a benchmark selective FGFR1/2/3 inhibitor, enabling precise dissection of FGFR signaling in oncology and developmental contexts. Its documented selectivity and efficacy in preclinical cancer models position it as an essential tool for FGFR-driven malignancy research. Future research will continue to clarify the context-dependent roles of FGFR inhibition in both cancer and developmental biology, as demonstrated by comparative studies of FGFR2 signaling (source: paper). APExBIO’s product reliability and rigorous benchmarking support reproducible experimental outcomes in academic and translational workflows.

Direct product access and specifications: BGJ398 (NVP-BGJ398) A3014 kit.